(Q35587108)

9 August 2017

1 reference

title

Utility of mould susceptibility testing (English)

1 reference

9 August 2017

1

Ana Espinel-Ingroff

1 reference

9 August 2017

language of work or name

English

1 reference

National Center for Biotechnology Information

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=14624101

3 April 2024

publication date

1 December 2003

1 reference

full work available at URL

9 August 2017

https://journals.lww.com/00001432-200312000-00003

1 reference

https://api.crossref.org/works/10.1097/00001432-200312000-00003

Current Opinion in Infectious Diseases

3 April 2024

published in

1 reference

9 August 2017

16

1 reference

9 August 2017

6

1 reference

9 August 2017

527-532

1 reference

Comparative evaluation of two different methods of inoculum preparation for antifungal susceptibility testing of filamentous fungi.

9 August 2017

1

1 reference

https://api.crossref.org/works/10.1097/00001432-200312000-00003

Conidial viability assay for rapid susceptibility testing of Aspergillus species

3 April 2024

2

1 reference

https://api.crossref.org/works/10.1097/00001432-200312000-00003

In vitro activities of investigational triazoles against Fusarium species: effects of inoculum size and incubation time on broth microdilution susceptibility test results

3 April 2024

3

1 reference

https://api.crossref.org/works/10.1097/00001432-200312000-00003

Voriconazole Treatment for Less‐Common, Emerging, or Refractory Fungal Infections

3 April 2024

4

1 reference

https://api.crossref.org/works/10.1097/00001432-200312000-00003

Optimal susceptibility testing conditions for detection of azole resistance in Aspergillus spp.: NCCLS collaborative evaluation. National Committee for Clinical Laboratory Standards

3 April 2024

5

1 reference

https://api.crossref.org/works/10.1097/00001432-200312000-00003

Azole cross-resistance in Aspergillus fumigatus

3 April 2024

6

1 reference

https://api.crossref.org/works/10.1097/00001432-200312000-00003

Nationwide survey of in vitro activities of itraconazole and voriconazole against clinical Aspergillus fumigatus isolates cultured between 1945 and 1998.

3 April 2024

7

1 reference

https://api.crossref.org/works/10.1097/00001432-200312000-00003

Do in vitro susceptibility data predict the microbiologic response to amphotericin B? Results of a prospective study of patients with Candida fungemia.

3 April 2024

8

1 reference

https://api.crossref.org/works/10.1097/00001432-200312000-00003

Experimental pulmonary aspergillosis due to Aspergillus terreus: pathogenesis and treatment of an emerging fungal pathogen resistant to amphotericin B.

3 April 2024

9

1 reference

https://api.crossref.org/works/10.1097/00001432-200312000-00003

Testing conditions for determination of minimum fungicidal concentrations of new and established antifungal agents for Aspergillus spp.: NCCLS collaborative study

3 April 2024

10

1 reference

https://api.crossref.org/works/10.1097/00001432-200312000-00003

Optimal testing conditions for determining MICs and minimum fungicidal concentrations of new and established antifungal agents for uncommon molds: NCCLS collaborative study

3 April 2024

11

1 reference

https://api.crossref.org/works/10.1097/00001432-200312000-00003

Evaluation of broth microdilution testing parameters and agar diffusion Etest procedure for testing susceptibilities of Aspergillus spp. to caspofungin acetate (MK-0991).

3 April 2024

12

1 reference

https://api.crossref.org/works/10.1097/00001432-200312000-00003

Lot-to-lot variability of antibiotic medium 3 used for testing susceptibility of Candida isolates to amphotericin B.

3 April 2024

13

1 reference

https://api.crossref.org/works/10.1097/00001432-200312000-00003

Influences of methodological variables on susceptibility testing of caspofungin against Candida species and Aspergillus fumigatus

3 April 2024

14

1 reference

https://api.crossref.org/works/10.1097/00001432-200312000-00003

Morphological effects of lipopeptides against Aspergillus fumigatus correlate with activities against (1,3)-beta-D-glucan synthase

3 April 2024

15

1 reference

https://api.crossref.org/works/10.1097/00001432-200312000-00003

Antifungal resistance in pathogenic fungi

3 April 2024

16

1 reference

https://api.crossref.org/works/10.1097/00001432-200312000-00003

In vitro activity of voriconazole, itraconazole, caspofungin, anidulafungin (VER002, LY303366) and amphotericin B against aspergillus spp.

3 April 2024

17

1 reference

https://api.crossref.org/works/10.1097/00001432-200312000-00003

E-test method for testing susceptibilities of Aspergillus spp. to the new triazoles voriconazole and posaconazole and to established antifungal agents: comparison with NCCLS broth microdilution method.

3 April 2024

18

1 reference

https://api.crossref.org/works/10.1097/00001432-200312000-00003

Comparison of the Sensititre YeastOne colorimetric antifungal panel and Etest with the NCCLS M38-A method to determine the activity of amphotericin B and itraconazole against clinical isolates of Aspergillus spp.

3 April 2024

19

1 reference

https://api.crossref.org/works/10.1097/00001432-200312000-00003

In vitro susceptibility testing of filamentous fungi: comparison of Etest and reference M38-A microdilution methods for determining posaconazole MICs

3 April 2024

20

1 reference

https://api.crossref.org/works/10.1097/00001432-200312000-00003

In vitro susceptibility testing of Aspergillus spp.: comparison of Etest and reference microdilution methods for determining voriconazole and itraconazole MICs

3 April 2024

21

1 reference

https://api.crossref.org/works/10.1097/00001432-200312000-00003

Scopulariopsis brevicaulis, a fungal pathogen resistant to broad-spectrum antifungal agents.

3 April 2024

22

1 reference

https://api.crossref.org/works/10.1097/00001432-200312000-00003

Activities of caspofungin, itraconazole, posaconazole, ravuconazole, voriconazole, and amphotericin B against 448 recent clinical isolates of filamentous fungi

3 April 2024

23

1 reference

https://api.crossref.org/works/10.1097/00001432-200312000-00003

In vitro activities of new and conventional antifungal agents against clinical Scedosporium isolates

3 April 2024

24

1 reference

https://api.crossref.org/works/10.1097/00001432-200312000-00003

In vitro drug interaction modeling of combinations of azoles with terbinafine against clinical Scedosporium prolificans isolates

3 April 2024

25

1 reference

https://api.crossref.org/works/10.1097/00001432-200312000-00003

Antifungal activities of posaconazole, ravuconazole, and voriconazole compared to those of itraconazole and amphotericin B against 239 clinical isolates of Aspergillus spp. and other filamentous fungi: report from SENTRY Antimicrobial Surveillance P

3 April 2024

26

1 reference

https://api.crossref.org/works/10.1097/00001432-200312000-00003

Laboratory evaluation of new antifungal agents against rare and refractory mycoses

3 April 2024

27

1 reference

https://api.crossref.org/works/10.1097/00001432-200312000-00003

In vitro susceptibilities of zygomycetes to conventional and new antifungals

3 April 2024

28

1 reference

https://api.crossref.org/works/10.1097/00001432-200312000-00003

In vitro activities of posaconazole, itraconazole, voriconazole, amphotericin B, and fluconazole against 37 clinical isolates of zygomycetes

3 April 2024

29

1 reference

https://api.crossref.org/works/10.1097/00001432-200312000-00003

Activity of posaconazole against Pseudallescheria boydii: in vitro and in vivo assays

3 April 2024

30

1 reference

https://api.crossref.org/works/10.1097/00001432-200312000-00003

Voriconazole in the treatment of aspergillosis, scedosporiosis and other invasive fungal infections in children

3 April 2024

32

1 reference

https://api.crossref.org/works/10.1097/00001432-200312000-00003

Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis

3 April 2024

33

1 reference

https://api.crossref.org/works/10.1097/00001432-200312000-00003

Invasive aspergillosis in 2002: an update

3 April 2024

34

1 reference

https://api.crossref.org/works/10.1097/00001432-200312000-00003

Epidemiology and outcome of mould infections in hematopoietic stem cell transplant recipients

3 April 2024

35

1 reference

https://api.crossref.org/works/10.1097/00001432-200312000-00003

Antifungal drug resistance of pathogenic fungi.

3 April 2024

36

1 reference

https://api.crossref.org/works/10.1097/00001432-200312000-00003

In vitro synergistic interaction between amphotericin B and pentamidine against Scedosporium prolificans.

3 April 2024

37

1 reference

https://api.crossref.org/works/10.1097/00001432-200312000-00003

In vitro synergy of caspofungin and amphotericin B against Aspergillus and Fusarium spp.

3 April 2024

38

1 reference

https://api.crossref.org/works/10.1097/00001432-200312000-00003

In vitro interaction of caspofungin acetate with voriconazole against clinical isolates of Aspergillus spp.

3 April 2024

39

1 reference

https://api.crossref.org/works/10.1097/00001432-200312000-00003

Differential activity of triazoles in two-drug combinations with the echinocandin caspofungin against Aspergillus fumigatus

3 April 2024

40

1 reference

https://api.crossref.org/works/10.1097/00001432-200312000-00003

Efficacy of caspofungin alone and in combination with voriconazole in a Guinea pig model of invasive aspergillosis

3 April 2024

41

1 reference

https://api.crossref.org/works/10.1097/00001432-200312000-00003

Scedosporium prolificans osteomyelitis in an immunocompetent child treated with voriconazole and caspofungin, as well as locally applied polyhexamethylene biguanide

3 April 2024

42

1 reference

https://api.crossref.org/works/10.1097/00001432-200312000-00003

Antifungal drug resistance to azoles and polyenes

3 April 2024

43

1 reference

https://api.crossref.org/works/10.1097/00001432-200312000-00003

Clinical relevance of mechanisms of antifungal drug resistance in filamentous fungi

3 April 2024

44

1 reference

https://api.crossref.org/works/10.1097/00001432-200312000-00003

Multidrug resistance in Aspergillus fumigatus.

3 April 2024

45

1 reference

https://api.crossref.org/works/10.1097/00001432-200312000-00003

Lack of correlation of in vitro amphotericin B susceptibility testing with outcome in a murine model of Aspergillus infection.

3 April 2024

46

1 reference

https://api.crossref.org/works/10.1097/00001432-200312000-00003

Activity of micafungin (FK463) against an itraconazole-resistant strain of Aspergillus fumigatus and a strain of Aspergillus terreus demonstrating in vivo resistance to amphotericin B.

3 April 2024

47

1 reference

https://api.crossref.org/works/10.1097/00001432-200312000-00003

Resistance to amphotericin B does not emerge during treatment for invasive aspergillosis

3 April 2024

48

1 reference

https://api.crossref.org/works/10.1097/00001432-200312000-00003

Correlation between in-vitro susceptibility testing to itraconazole and in-vivo outcome of Aspergillus fumigatus infection

3 April 2024

49

1 reference

https://api.crossref.org/works/10.1097/00001432-200312000-00003

Increased expression of a novel Aspergillus fumigatus ABC transporter gene, atrF, in the presence of itraconazole in an itraconazole resistant clinical isolate

3 April 2024

50

1 reference

https://api.crossref.org/works/10.1097/00001432-200312000-00003

Multiple resistance mechanisms among Aspergillus fumigatus mutants with high-level resistance to itraconazole.

3 April 2024

51

1 reference

https://api.crossref.org/works/10.1097/00001432-200312000-00003

A point mutation in the 14alpha-sterol demethylase gene cyp51A contributes to itraconazole resistance in Aspergillus fumigatus

3 April 2024

52

1 reference

https://api.crossref.org/works/10.1097/00001432-200312000-00003

Resistance to itraconazole in Aspergillus nidulans and Aspergillus fumigatus is conferred by extra copies of the A. nidulans P-450 14alpha-demethylase gene, pdmA.

3 April 2024

53

1 reference

https://api.crossref.org/works/10.1097/00001432-200312000-00003

Mutations in Aspergillus fumigatus resulting in reduced susceptibility to posaconazole appear to be restricted to a single amino acid in the cytochrome P450 14alpha-demethylase

3 April 2024

54

1 reference

https://api.crossref.org/works/10.1097/00001432-200312000-00003

Glucan synthase inhibitors as antifungal agents

3 April 2024

55

1 reference

https://api.crossref.org/works/10.1097/00001432-200312000-00003

Comparative antifungal activities and plasma pharmacokinetics of micafungin (FK463) against disseminated candidiasis and invasive pulmonary aspergillosis in persistently neutropenic rabbits

3 April 2024

56

1 reference

https://api.crossref.org/works/10.1097/00001432-200312000-00003

Pseudallescheria boydii (Anamorph Scedosporium apiospermum). Infection in solid organ transplant recipients in a tertiary medical center and review of the literature

3 April 2024

57

1 reference

https://api.crossref.org/works/10.1097/00001432-200312000-00003

In-vitro testing of susceptibility to amphotericin B is a reliable predictor of clinical outcome in invasive aspergillosis.

3 April 2024

58

1 reference

https://api.crossref.org/works/10.1097/00001432-200312000-00003

In vivo activity of posaconazole against Mucor spp. in an immunosuppressed-mouse model

3 April 2024

60

1 reference

https://api.crossref.org/works/10.1097/00001432-200312000-00003

In vitro and in vivo activities of posaconazole against Coccidioides immitis

3 April 2024

61

1 reference

https://api.crossref.org/works/10.1097/00001432-200312000-00003

Single- and multiple-dose pharmacokinetics of caspofungin in healthy men.

3 April 2024

62

1 reference

https://api.crossref.org/works/10.1097/00001432-200312000-00003

3 April 2024

Identifiers

1 reference

9 August 2017

1 reference